Related posts

Markets weaken amid earningsSell-off continues, Bitcoin downRally continues after more tame inflation data
Investor Insights

This summary was created by AI, based on 41 opinions in the last 12 months.

Experts are largely bullish on Eli Lilly & Co., citing the company's strong technical momentum, compelling fundamental story, and promising drug pipeline. There is also consensus on the potential of their weight-loss drugs and their position in the healthcare market. However, some caution against the high valuation and the need for a price correction before buying.

Consensus
Bullish
Valuation
Overvalued
BUY
Eli Lilly & Co.

Chart's in an uptrend. Nothing nasty going on. Flattening, pulling back a bit. Good chart. Keep owning, and you could actually add to your position. Healthcare's not doing too badly as a sector.

biotechnology / pharmaceutical
DON'T BUY
Eli Lilly & Co.
LLY vs. MRK

Valuation has skyrocketed as a beneficiary of GLP-1 drugs, so MRK gets the nod. Good job developing products.

biotechnology / pharmaceutical
DON'T BUY
Eli Lilly & Co.

Is doing very well but is risky because it's trading at far higher multiple than its peers. If there's competition in their obesity drug, shares will sink.

biotechnology / pharmaceutical
COMMENT
Eli Lilly & Co.

Debt-to-equity continues to climb. He rebalanced his portfolio and sold this. Still a good stock that he targets $900 for. It trades like a biotech.

biotechnology / pharmaceutical
WATCH
Eli Lilly & Co.

It reports Tuesday. He expects good numbers because their obesity drug keeps selling out, but they can't produce it fast enough which could impair the top and bottom lines.

biotechnology / pharmaceutical
SELL ON STRENGTH
Eli Lilly & Co.

Obesity space has performed well lately. Has owned stock for around two years. Valuation has continued to improve. Products are very profitable. Demand for new drugs continue to rise. Would recommend keeping at small weight in portfolio - share price very high. Very competitive industry within drug sector. 

biotechnology / pharmaceutical
HOLD
Eli Lilly & Co.

It peaked in early March but remains resilient. It benefits from other health companies not announcing news that excites investors. LLY is universally owned.

biotechnology / pharmaceutical
COMMENT
Eli Lilly & Co.
vs. Novo Nordisk

It's too early to tell what the long-term results of the weight-loss drugs, but short term people are buying them. You need to know a lot of tech and chemistry to understand pharma stocks and he doesn't care to do that. If you believe their drug prices will fall and more people will use them, then these share will rise.

biotechnology / pharmaceutical
TOP PICK
Eli Lilly & Co.

Excellent technical momentum. Highly ranked from technical perspective. Performance very good the past year. Outperforming sector overall. Very skilled management team with strong brand. 

biotechnology / pharmaceutical
HOLD
Eli Lilly & Co.
Upgraded today

Agrees with this call. Obesity drugs remain a big opportunity within healthcare, a $100-billion market by 2030, says Goldman; half the world's population would qualify by then. True, LLY is expensive at 55x forward PE, he still likes and owns this. He may trim at a higher price.

biotechnology / pharmaceutical
COMMENT
Eli Lilly & Co.
Upgraded today

Their popular obesity drug is like AI--a lot is already priced in, though the obesity drug may be applicable to other ailments.

biotechnology / pharmaceutical
SELL
Eli Lilly & Co.

Big difference between a company and a stock. It's like buying a jacket for different price points of $1000, $300, or on sale for $150. You make an investment/purchase decision. 

LLY and NVO are great companies, but you have to look at how expensive they are. Quite expensive at around 50x earnings. Good growth rates. A reasonable multiple for a drug company is sub-20x, and these won't get there via discounted cashflow until next decade. That's a long way out.

He looks for things that have yet to be priced properly. He owns MRK.

biotechnology / pharmaceutical
BUY
Eli Lilly & Co.
Upgraded today

The fundamental story is compelling, enjoying momentum and a technical breakout, but it could pause before it resumes its climb.

biotechnology / pharmaceutical
BUY
Eli Lilly & Co.

A drug approval was delayed and shares are down only 2% today. If there's a market correction, LLY will also fall. But their fundamental story has not changed and he still believes in it.

biotechnology / pharmaceutical
BUY
Eli Lilly & Co.

Was upgraded today. It trades like a biotech. The response to their strong earnings on Feb. 6 has been purely positive, rallying. The catalyst are the momentum funds buying this which have a 5% weighting in LLY. Also, the fundamentals are in place.

biotechnology / pharmaceutical
Showing 1 to 15 of 122 entries

Eli Lilly & Co.(LLY-N) Rating

Ranking : 5 out of 5

Bullish - Buy Signals / Votes : 23

Neutral - Hold Signals / Votes : 4

Bearish - Sell Signals / Votes : 9

Total Signals / Votes : 36

Stockchase rating for Eli Lilly & Co. is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Eli Lilly & Co.(LLY-N) Frequently Asked Questions

What is Eli Lilly & Co. stock symbol?

Eli Lilly & Co. is a American stock, trading under the symbol LLY-N on the New York Stock Exchange (LLY). It is usually referred to as NYSE:LLY or LLY-N

Is Eli Lilly & Co. a buy or a sell?

In the last year, 36 stock analysts published opinions about LLY-N. 23 analysts recommended to BUY the stock. 9 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Eli Lilly & Co..

Is Eli Lilly & Co. a good investment or a top pick?

Eli Lilly & Co. was recommended as a Top Pick by on . Read the latest stock experts ratings for Eli Lilly & Co..

Why is Eli Lilly & Co. stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Eli Lilly & Co. worth watching?

36 stock analysts on Stockchase covered Eli Lilly & Co. In the last year. It is a trending stock that is worth watching.

What is Eli Lilly & Co. stock price?

On 2024-05-23, Eli Lilly & Co. (LLY-N) stock closed at a price of $808.45.